Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) EBIT (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed EBIT for 17 consecutive years, with -$2.1 million as the latest value for Q1 2026.

  • Quarterly EBIT fell 120.58% to -$2.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$5.4 million through Jan 2026, up 17.18% year-over-year, with the annual reading at -$4.4 million for FY2025, 48.62% up from the prior year.
  • EBIT for Q1 2026 was -$2.1 million at PharmaCyte Biotech, down from -$1.4 million in the prior quarter.
  • The five-year high for EBIT was -$848305.0 in Q3 2025, with the low at -$3.2 million in Q2 2024.
  • Average EBIT over 5 years is -$1.5 million, with a median of -$1.4 million recorded in 2023.
  • The sharpest move saw EBIT plummeted 250.52% in 2024, then soared 67.09% in 2025.
  • Over 5 years, EBIT stood at -$2.3 million in 2022, then skyrocketed by 39.21% to -$1.4 million in 2023, then rose by 21.53% to -$1.1 million in 2024, then fell by 24.41% to -$1.4 million in 2025, then plummeted by 53.93% to -$2.1 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$2.1 million, -$1.4 million, and -$848305.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.